共 50 条
- [1] Efficacy of Prinomastat® (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularizationCURRENT EYE RESEARCH, 2002, 24 (01) : 33 - 38Garcia, CRBartsch, DURivero, MEHagedorn, MMcDermott, CDBergeron-Lynn, GCheng, LYAppelt, KFreeman, WR
- [2] A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancerANNALS OF ONCOLOGY, 1998, 9 : 74 - 74Hande, KWilding, GRipple, GFry, JArzoomanian, RDixon, MYuen, GCollier, M
- [3] Phase I study of AG3340, a matrix metalloprotease inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancerANNALS OF ONCOLOGY, 1998, 9 : 74 - 74Wilding, GSmall, ERipple, GKeller, MYuen, GCollier, M
- [4] Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaINVESTIGATIONAL NEW DRUGS, 2006, 24 (02) : 135 - 140Heath, EIBurtness, BAKleinberg, LSalem, RRYang, SCHeitmiller, RFCanto, MIKnisely, JPSTopazian, MMontgomery, ETsottles, NPithavala, YRohmiller, BCollier, MForastiere, AA
- [5] Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaInvestigational New Drugs, 2006, 24 : 135 - 140Elisabeth I. HeathBarbara A. BurtnessLawrence KleinbergRonald R. SalemStephen C. YangRichard F. HeitmillerMarcia I. CantoJonathan P. S. KniselyMark TopazianElizabeth MontgomeryNancy TsottlesYazdi PithavalaBridget RohmillerMary CollierArlene A. Forastiere
- [6] A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)BLOOD, 2020, 136Morita, KiyomiKantarjian, Hagop M.Bravo, Guillermo MontalbanSasaki, KojiDaver, NavalJabbour, EliasAlvarado, YesidChien, Kelly S.DiNardo, Courtney D.Ravandi, FarhadBorthakur, GautamBose, PrithvirajPemmaraju, NaveenNaqvi, KiranCortes, Jorge E.Kadia, Tapan M.Konopleva, MarinaRausch, Caitlin R.Gasior, YvonneGarcia-Manero, Guillermo
- [7] Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic OsteosarcomaJOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) : 1424 - +Davis, Lara E.Bolejack, VanessaRyan, Christopher W.Ganjoo, Kristen N.Loggers, Elizabeth T.Chawla, SantAgulnik, MarkLivingston, Michael B.Reed, DamonKeedy, VickyRushing, DanielOkuno, ScottReinke, Denise K.Riedel, Richard F.Attia, StevenMascarenhas, LeoMaki, Robert G.
- [8] Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Cashen, A. F.Juckett, A.Jumonville, A.Litzow, M. R.Flynn, P. J.Eckardt, J. R.LaPlant, B.Laumann, K. M.Erlichman, C.DiPersio, J. F.
- [9] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1BLOOD, 2019, 134Zeidan, Amer M.Miyazaki, YasushiPlatzbecker, UweMalek, KamelNiolat, JulieKiertsman, FlaviaFenaux, Pierre
- [10] A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)BLOOD, 2018, 132Garcia-Manero, GuillermoSasaki, KojiMontalban-Bravo, GuillermoDaver, Naval G.Jabbour, Elias J.Alvarado, YesidDiNardo, Courtney D.Ravandi, FarhadBorthakur, GautamBose, PrithvirajPemmaraju, NaveenNaqvi, KiranCortes, Jorge E.Kadia, Tapan M.Konopleva, Marina Y.Colla, SimonaYang, HuiRausch, Caitlin R.Gasior, YvonneBueso-Ramos, Carlos E.Kanagal-Shamanna, RashmiPatel, Keyur P.Kantarjian, Hagop M.